{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:12:50Z","timestamp":1792271570313,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Adult-onset Still\u2019s disease (AOSD) is a multi-system, auto-inflammatory disease characterized by fever, arthralgia, typical rash, leukocytosis, sore throat, and liver dysfunction, among other symptoms. Retrospective studies about the frequencies of AOSD have shown that this disease is very rare. However, there has been an increased scientific interest in the last 2 years, as numerous case studies on AOSD have been published. These case studies describe the occurrence of AOSD after SARS-CoV-2 infection and\/or COVID-19 vaccination.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analyzed the incidence of AOSD to examine a potential association between AOSD and SARS-CoV-2 infection and\/or COVID-19 vaccination. The TriNetX dataset consists of 90 million patients. We found 8474 AOSD cases, which we analyzed regarding SARS-CoV-2 infection and\/or vaccination status. We also analyzed the cohorts considering demographic data, lab values, co-diagnoses and treatment pathways.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We divided the AOSD cases into four cohorts: primary cohort (AOSD), Cov cohort (AOSD\u2009+\u2009SARS-CoV-2 infection), Vac cohort (AOSD\u2009+\u2009COVID-19 vaccination) and Vac\u2009+\u2009Cov cohort (AOSD\u2009+\u2009COVID-19 vaccination\u2009+\u2009SARS-CoV-2 infection). For the primary cohort, we found an annual incidence of 0.35 per 100.000. We found an association between AOSD and SARS-CoV-2 infection and\/or COVID-19 vaccination. According to the numerical analysis, the incidence of AOSD doubled for the Cov cohort and Vac cohort. Moreover, the incidence of AOSD was 4.82 times higher for Vac\u2009+\u2009Cov cohort. The lab values for inflammatory markers were increased. Co-diagnoses such as rash, sore throat, and fever appeared in all AOSD cohorts, with the highest occurrences in the AOSD\u2009+\u2009COVID-19 vaccination\u2009+\u2009SARS-CoV-2 infection cohort. We identified several lines of treatments, mainly in association with adrenal corticosteroids.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This research supports the assumption of an association between AOSD and SARS-CoV-2 infection and\/or COVID-19 vaccination. However, AOSD remains a rare disease and the usage of vaccines to fight the COVID-19 pandemic should not be questioned because of the increased incidence of AOSD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-023-02651-3","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T08:03:16Z","timestamp":1678435396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Increased incidence of adult-onset Still\u2019s disease in association with COVID-19 vaccination and SARS-CoV-2 infection"],"prefix":"10.1186","volume":"18","author":[{"given":"Maxime N.","family":"Gottschalk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Heiland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Nahles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Preissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Petri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Wendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3672-0283","authenticated-orcid":false,"given":"Saskia","family":"Preissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"issue":"2","key":"2651_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1136\/ard.30.2.121","volume":"30","author":"EG Bywaters","year":"1971","unstructured":"Bywaters EG. Still\u2019s disease in the adult. Ann Rheum Dis. 1971;30(2):121\u201333.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2651_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/07853890.2014.971052","volume":"47","author":"S Kadavath","year":"2015","unstructured":"Kadavath S, Efthimiou P. Adult-onset Still\u2019s disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med. 2015;47(1):6\u201314.","journal-title":"Ann Med"},{"issue":"3","key":"2651_CR3","first-page":"424","volume":"19","author":"M Yamaguchi","year":"1992","unstructured":"Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still\u2019s disease. J Rheumatol. 1992;19(3):424\u201330.","journal-title":"J Rheumatol"},{"issue":"3","key":"2651_CR4","first-page":"196","volume":"23","author":"L Shechtman","year":"2021","unstructured":"Shechtman L, Lahad K, Ben-Zvi I. Adult Still\u2019s disease triggered by influenza vaccine. Isr Med Assoc J. 2021;23(3):196\u20137.","journal-title":"Isr Med Assoc J"},{"issue":"4","key":"2651_CR5","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.semarthrit.2021.06.004","volume":"51","author":"P Efthimiou","year":"2021","unstructured":"Efthimiou P, Kontzias A, Hur P, Rodha K, Ramakrishna GS, Nakasato P. Adult-onset Still\u2019s disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. Semin Arthritis Rheum. 2021;51(4):858\u201374.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"2651_CR6","first-page":"818","volume":"33","author":"MA Balci","year":"2015","unstructured":"Balci MA, Pamuk ON, Pamuk GE, Uzundere FK, Donmez S. Epidemiology and outcome of adult-onset Still\u2019s disease in Northwestern Thrace region in Turkey. Clin Exp Rheumatol. 2015;33(6):818\u201323.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"2651_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/03009740510026616","volume":"35","author":"KJ Evensen","year":"2006","unstructured":"Evensen KJ, Nossent HC. Epidemiology and outcome of adult-onset Still\u2019s disease in Northern Norway. Scand J Rheumatol. 2006;35(1):48\u201351.","journal-title":"Scand J Rheumatol"},{"issue":"7","key":"2651_CR8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/ard.54.7.587","volume":"54","author":"G Magadur-Joly","year":"1995","unstructured":"Magadur-Joly G, Billaud E, Barrier JH, Pennec YL, Masson C, Renou P, et al. Epidemiology of adult Still\u2019s disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis. 1995;54(7):587\u201390.","journal-title":"Ann Rheum Dis"},{"issue":"33","key":"2651_CR9","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1055\/s-0031-1281572","volume":"136","author":"C Dechant","year":"2011","unstructured":"Dechant C, Kruger K. Adult-onset Still\u2019s disease. Dtsch Med Wochenschr. 2011;136(33):1669\u201373.","journal-title":"Dtsch Med Wochenschr"},{"issue":"7","key":"2651_CR10","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","volume":"13","author":"M Gerfaud-Valentin","year":"2014","unstructured":"Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Seve P. Adult-onset Still\u2019s disease. Autoimmun Rev. 2014;13(7):708\u201322.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"2651_CR11","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1016\/S2665-9913(21)00072-2","volume":"3","author":"AD Bamidis","year":"2021","unstructured":"Bamidis AD, Koehler P, di Cristanziano V, Rasche K, Demirel B, Bacher P, et al. First manifestation of adult-onset Still\u2019s disease after COVID-19. Lancet Rheumatol. 2021;3(5):e319\u201321.","journal-title":"Lancet Rheumatol"},{"key":"2651_CR12","first-page":"317820","volume":"2012","author":"C Giampietro","year":"2012","unstructured":"Giampietro C, Fautrel B. Anti-interleukin-1 agents in adult onset Still\u2019s disease. Int J Inflam. 2012;2012:317820.","journal-title":"Int J Inflam"},{"key":"2651_CR13","doi-asserted-by":"publisher","first-page":"117954762199630","DOI":"10.1177\/1179547621996306","volume":"14","author":"A Alshablan","year":"2021","unstructured":"Alshablan A, Jabbad R, Tayeb S, Albeshri T, Yelamanchili SR, Rabie N, et al. Diagnosis of adult onset Still\u2019s disease in a patient who has recovered from coronavirus-19. Clin Med Insights Case Rep. 2021;14:1179547621996306.","journal-title":"Clin Med Insights Case Rep"},{"issue":"10","key":"2651_CR14","doi-asserted-by":"publisher","first-page":"e678","DOI":"10.1016\/S2665-9913(21)00218-6","volume":"3","author":"F Leone","year":"2021","unstructured":"Leone F, Cerasuolo PG, Bosello SL, Verardi L, Fiori E, Cocciolillo F, et al. Adult-onset Still\u2019s disease following COVID-19 vaccination. Lancet Rheumatol. 2021;3(10):e678\u201380.","journal-title":"Lancet Rheumatol"},{"key":"2651_CR15","doi-asserted-by":"publisher","first-page":"108878","DOI":"10.1016\/j.clim.2021.108878","volume":"233","author":"A Sharabi","year":"2021","unstructured":"Sharabi A, Shiber S, Molad Y. Adult-onset Still\u2019s disease following mRNA COVID-19 vaccination. Clin Immunol. 2021;233:108878.","journal-title":"Clin Immunol"},{"issue":"12","key":"2651_CR16","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1111\/imj.15563","volume":"51","author":"A Sweeney","year":"2021","unstructured":"Sweeney A, Tracey G, Garnham K. Adult-onset Still disease post-adenovirus vector COVID-19 vaccine. Intern Med J. 2021;51(12):2144\u20135.","journal-title":"Intern Med J"},{"issue":"10","key":"2651_CR17","doi-asserted-by":"publisher","first-page":"e680","DOI":"10.1016\/S2665-9913(21)00219-8","volume":"3","author":"D Magliulo","year":"2021","unstructured":"Magliulo D, Narayan S, Ue F, Boulougoura A, Badlissi F. Adult-onset Still\u2019s disease after mRNA COVID-19 vaccine. Lancet Rheumatol. 2021;3(10):e680\u20132.","journal-title":"Lancet Rheumatol"},{"issue":"50","key":"2651_CR18","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.3346\/jkms.2021.36.e344","volume":"36","author":"SY Park","year":"2021","unstructured":"Park SY, Lee KH. Adult-onset Still\u2019s disease after BNT162b2 mRNA COVID-19 Vaccine. J Korean Med Sci. 2021;36(50):e344.","journal-title":"J Korean Med Sci"},{"issue":"2","key":"2651_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.semarthrit.2017.06.006","volume":"47","author":"G Junge","year":"2017","unstructured":"Junge G, Mason J, Feist E. Adult onset Still\u2019s disease-the evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review). Semin Arthritis Rheum. 2017;47(2):295\u2013302.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"2651_CR20","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s10067-022-06124-z","volume":"41","author":"R Roongta","year":"2022","unstructured":"Roongta R, Mondal S, Haldar S, Kumar MS, Ghosh A. Two flares of Still\u2019s disease after two doses of the ChAdOx1 vaccine. Clin Rheumatol. 2022;41(5):1591\u20136.","journal-title":"Clin Rheumatol"},{"key":"2651_CR21","doi-asserted-by":"publisher","DOI":"10.12932\/AP-100121-1033","author":"K Jatuworapruk","year":"2021","unstructured":"Jatuworapruk K. Adult-onset Stills disease preceded by influenza vaccination: coincidence or true association. Asian Pac J Allergy Immunol. 2021. https:\/\/doi.org\/10.12932\/AP-100121-1033.","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"4","key":"2651_CR22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3109\/s10165-011-0418-7","volume":"21","author":"K Yoshioka","year":"2011","unstructured":"Yoshioka K, Fujimoto S, Oba H, Minami M, Aoki T. Onset of adult-onset Still\u2019s disease following influenza vaccination. Mod Rheumatol. 2011;21(4):432\u20135.","journal-title":"Mod Rheumatol"},{"issue":"4","key":"2651_CR23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1177\/15353702211070290","volume":"247","author":"S Bindoli","year":"2022","unstructured":"Bindoli S, Giollo A, Galozzi P, Doria A, Sfriso P. Hyperinflammation after anti-SARS-CoV-2 mRNA\/DNA vaccines successfully treated with anakinra: case series and literature review. Exp Biol Med. 2022;247(4):338\u201344.","journal-title":"Exp Biol Med"},{"issue":"7872","key":"2651_CR24","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-021-03791-x","volume":"596","author":"PS Arunachalam","year":"2021","unstructured":"Arunachalam PS, Scott MKD, Hagan T, Li C, Feng Y, Wimmers F, et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature. 2021;596(7872):410\u20136.","journal-title":"Nature"},{"key":"2651_CR25","unstructured":"TriNetX. Publication Guidelines [Available from: https:\/\/trinetx.com\/trinetx-publication-guidelines\/. Accessed April 6 2022."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02651-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02651-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02651-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T08:06:21Z","timestamp":1678435581000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02651-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2651"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02651-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,10]]},"assertion":[{"value":"4 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TriNetX is compliant with the Health Insurance Portability and Accountability Act (HIPAA), the U.S. federal law that protects the privacy and security of health care data. TriNetX is certified according to the ISO 27001:2013 standard and maintains an Information Security Management System (ISMS) to ensure the protection of the health care data it has access to and to meet the HIPAA requirements. Any data displayed on the TriNetX platform in aggregate form or any patient-level data provided in a data set generated by the TriNetX platform only contains de-identified data as per the de-identification standard defined in Section 164.514(a) of the HIPAA Privacy Rule. The process by which the data are de-identified is attested to through a formal determination by a qualified expert as defined in Section 164.514(b) (1) of the HIPAA Privacy Rule. This formal determination by a qualified expert, refreshed in December 2020, supersedes the need for TriNetX\u2019s previous waiver from the Western Institutional Review Board (IRB). The TriNetX network contains data provided by participating HCOs, each of which represents and warrants that it has all necessary rights, consents, approvals, and authority to provide the data to TriNetX under a business associate agreement (BAA), so long as their name remains anonymous as a data source and their data are utilized for research purposes. The data shared through the TriNetX platform are attenuated to ensure that they do not include sufficient information to facilitate the determination of which HCO contributed which specific information about a patient [].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}